High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia
- PMID: 31892526
- PMCID: PMC7053836
- DOI: 10.1194/jlr.P119000473
High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia
Abstract
Whether HDL is associated with dementia risk is unclear. In addition to apoA1, other apolipoproteins are found in HDL, creating subspecies of HDL that may have distinct metabolic properties. We measured apoA1, apoC3, and apoJ levels in plasma and apoA1 levels in HDL that contains or lacks apoE, apoJ, or apoC3 using a modified sandwich ELISA in a case-cohort study nested within the Ginkgo Evaluation of Memory Study. We included 995 randomly selected participants and 521 participants who developed dementia during a mean of 5.1 years of follow-up. The level of total apoA1 was not significantly related to dementia risk, regardless of the coexistence of apoC3, apoJ, or apoE. Higher levels of total plasma apoC3 were associated with better cognitive function at baseline (difference in Modified Mini-Mental State Examination scores tertile 3 vs. tertile 1: 0.60; 95% CI: 0.23, 0.98) and a lower dementia risk (adjusted hazard ratio tertile 3 vs. tertile 1: 0.73; 95% CI: 0.55, 0.96). Plasma concentrations of apoA1 in HDL and its apolipoprotein-defined subspecies were not associated with cognitive function at baseline or with the risk of dementia during follow-up. Similar studies in other populations are required to better understand the association between apoC3 and Alzheimer's disease pathology.
Keywords: Alzheimer’s disease; aging; cognition; epidemiology.
Copyright © 2020 Koch et al.
Conflict of interest statement
The funding sources had no role in study design; in the collection, analysis, and interpretation of the data; in the writing of the report; or in the decision to submit the article for publication. The authors declare that they have no conflicts of interest with the contents of this article.
Figures
References
-
- Alzheimer’s Association. 2017. 2017 Alzheimer’s disease facts and figures. Alzheimers Dement. 13: 325–373.
-
- Olsson B., Lautner R., Andreasson U., Ohrfelt A., Portelius E., Bjerke M., Holtta M., Rosen C., Olsson C., Strobel G., et al. . 2016. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 15: 673–684. - PubMed
-
- Karlawish J., Jack C. R. Jr., Rocca W. A., Snyder H. M., and Carrillo M. C.. 2017. Alzheimer’s disease: the next frontier—special report 2017. Alzheimers Dement. 13: 374–380. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
